OV
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Dissecting apicoplast functions through continuous cultivation of Toxoplasma gondii devoid of the organelle | Nature communications |  | 2025 | 115 | 29 | ||
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | 2024 | 84 | 82 | ||
| N-acetylglucosamine supplementation fails to bypass the critical acetylation of glucosamine-6-phosphate required for Toxoplasma gondii replication and invasion | PLOS pathogens | | 2024 | 133 | 27 | ||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | 2023 | 64 | 24 | ||
| Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins | iScience | | 2023 | 87 | 34 | ||
| Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model | AACR Annual Meeting 2023 | | 2023 | 55 | 63 | ||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | 2022 | 69 | 80 | ||
| Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology | Molecular therapy. Methods & clinical development | | 2022 | 202 | 123 |
